Product nameCiglitazone, PPARgamma agonist
DescriptionSelective PPARγ agonist
Storage instructionsStore at Room Temperature. The product can be stored for up to 12 months.
Solubility overviewSoluble in DMSO to 100 mM and 1eq. NaOH to 100 mM
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
Our Abpromise guarantee covers the use of ab141139 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|Functional Studies||Use at an assay dependent concentration.|
ab19481 staining PPARγ in U-87 MG cells treated with ciglitazone (ab141139), by ICC/IF. Increase of PPARγ cytoplasmic expression correlates with increased concentration of ciglitazone, as described in literature.
The cells were incubated at 37°C for 24 hours in media containing different concentrations of ab141139 (ciglitazone) in DMSO, fixed with 4% formaldehyde for 10 minutes at room temperature and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab19481 (5 µg/ml) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody. Nuclei were counterstained with DAPI and are shown in blue.
This product has been referenced in:
- Plissonnier ML et al. The antidiabetic drug ciglitazone induces high grade bladder cancer cells apoptosis through the up-regulation of TRAIL. PLoS One 6:e28354 (2011). Read more (PubMed: 22174792) »
- Botton T et al. In vitro and in vivo anti-melanoma effects of ciglitazone. J Invest Dermatol 129:1208-18 (2009). Read more (PubMed: 19177142) »
- Willson TM et al. The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem 39:665-8 (1996). Read more (PubMed: 8576907) »